Apple WWDC: Unleashing the Power of AI and Spatial Computing with Groundbreaking Updates

The recent Apple Worldwide Developers Conference (WWDC) showcased significant updates across Apple’s platforms, introducing new features and enhancements designed to elevate user experience and developer capabilities. The event highlighted advancements in AI, updates to various operating systems, and notable improvements in Apple’s hardware and services. Key…

MIT Faculty Founder Initiative announces three winners of entrepreneurship awards

Patients with intractable cancers, chronic pain sufferers, and people who depend on battery-powered medical implants may all benefit from the ideas presented at the 2023-24 MIT-Royalty Pharma Prize Competition’s recent awards. This year’s top prizes went to researchers and biotech entrepreneurs Anne Carpenter, Frederike Petzschner, and Betar Gallant ’08, SM ’10, PhD ’13.

MIT Faculty Founder Initiative Executive Director Kit Hickey MBA ’13 describes the time and hard work the three awardees and other finalists devoted to the initiative and its mission of cultivating female faculty in biotech to cross the chasm between laboratory research and its clinical application.

“They have taken the first brave step of getting off the bench when they already work seven days a week. They have carved out time from their facilities, from their labs, from their lives in order to put themselves out there and leap into entrepreneurship,” Hickey says. “They’ve done it because they each want to see their innovations out in the world improving patients’ lives.”

Carpenter, senior director of the Imaging Platform at the Broad Institute of MIT and Harvard, where she is also an institute scientist, won the competition’s $250,000 2023-24 MIT-Royalty Pharma Faculty Founder Prize Competition Grand Prize. Carpenter specializes in using microscopy imaging of cells and computational methods such as machine learning to accelerate the identification of chemical compounds with therapeutic potential to, for instance, shrink tumors. The identified compounds are then tested in biological assays that model the tumor ecosystem to see how the compounds would perform on actual tumors.

Carpenter’s startup, SyzOnc, launched in April, a feat Carpenter associates with the assistance provided by the MIT Faculty Founder Initiative. Participants in the program receive mentorship, stipends, and advice from industry experts, as well as help with incorporating, assembling a management team, fundraising, and intellectual property strategy.

“The program offered key insights and input at major decision points that gave us the momentum to open our doors,” Carpenter says, adding that participating “offered validation of our scientific ideas and business plan. That kind of credibility is really helpful to raising funding, particularly for those starting their first company.”

Carpenter says she and her team will employ “the best biological and computational advancements to develop new therapies to fight tumors such as sarcoma, pancreatic cancer, and glioblastoma, which currently have dismal survival rates.”

The MIT Faculty Founder Initiative was begun in 2020 by the School of Engineering and the Martin Trust Center for MIT Entrepreneurship, based on research findings by Sangeeta Bhatia, the Wilson Professor of Health Sciences and Technology, professor of electrical engineering and computer science, and faculty director of the MIT Faculty Founder Initiative; Susan Hockfield, MIT Corporation life member, MIT president emerita, and professor of neuroscience; and Nancy Hopkins, professor emerita of biology. An investigation they conducted showed that only about 9 percent of MIT’s 250 biotech startups were started by women, whereas women made up 22 percent of the faculty, as was presented in a 2021 MIT Faculty Newsletter.

That data showed that “technologies from female labs were not getting out in the world, resulting in lost potential,” Hickey says.

“The MIT Faculty Founder Initiative plays a pivotal role in MIT’s entrepreneurship ecosystem. It elevates visionary faculty working on solutions in biotech by providing them with critical mentorship and resources, ensuring these solutions can be rapidly scaled to market,” says Anantha Chandrakasan, MIT’s chief innovation and strategy officer, dean of engineering, and Vannevar Bush Professor of Electrical Engineering and Computer Science.

The MIT Faculty Founder Initiative Prize Competition was launched in 2021. At this year’s competition, the judges represented academia, health care, biotech, and financial investment. In addition to awarding a grand prize, the competition also distributed two $100,000 prizes, one to a researcher from Brown University, the first university to collaborate with MIT in the entrepreneurship program.

This year’s winner of the $100,000 2023-24 MIT-Royalty Pharma Faculty Founder Prize Competition Runner-Up Prize was Frederike Petzschner, assistant professor at the Carney Institute for Brain Science at Brown, for her SOMA startup’s digital pain management system, which helps sufferers to manage and relieve chronic pain.

“We leverage cutting-edge technology to provide precision care, focusing specifically on personalized cognitive interventions tailored to each patient’s unique needs,” she says.

With her startup on the verge of incorporating, Petzschner says, “without the Faculty Finder Initiative, our startup would still be pursuing commercialization, but undoubtedly at a much earlier and perhaps less structured stage.”

“The constant support from the program organizers and our mentors was truly transformative,” she says.

Gallant, associate professor of mechanical engineering at MIT and winner of the $100,000 2023-24 MIT-Royalty Pharma Faculty Founder Prize Competition Breakthrough Prize, is leading the startup Halogen. An expert on advanced battery technologies, Gallant and her team have developed high-density battery storage to improve the lifetime and performance of such medical devices as pacemakers.

“If you can extend lifetime, you’re talking about longer times between invasive replacement surgeries, which really affects patient quality of life,” Gallant told MIT News in a 2022 interview.

Jim Reddoch, executive vice president and chief scientific officer of sponsor Royalty Pharma, emphasized his company’s support for both the competition and the MIT Faculty Finder Initiative program.

“Royalty Pharma is thrilled to support the 2023-2024 MIT-Royalty Pharma Prize Competition and accelerate life sciences innovation at leading research institutions such as MIT and Brown,” Reddoch says. “By supporting the amazing female entrepreneurs in this program, we hope to catalyze more ideas from the lab to biotech companies and eventually into the hands of patients.”

Bhatia has referred to the MIT Faculty Founder Initiative as a “playbook” on how to direct female faculty’s high-impact technologies that are not being commercialized into the world of health care.

“To me, changing the game means that when you have an invention in your lab, you’re connected enough to the ecosystem to know when it should be a company, and to know who to call and how to get your first investors and how to quickly catalyze your team — and you’re off to the races,” Bhatia says. “Every one one of those inventions can be a medicine as quickly as possible. That’s the future I imagine.”

Co-founder Hockfield referred to MIT’s role in promoting entrepreneurship in remarks at the award ceremony, alluding to Brown University’s having joined the effort.

“MIT has always been a leader in entrepreneurship,” Hockfield says. “Part of leading is sharing with the world. The collaboration with Brown University for this cohort shows that MIT can share our approach with the world, allowing other universities to follow our model of supporting academic entrepreneurship.”

Hickey says that when she and Bhatia asked 30 female faculty members three years ago why they were not commercializing their technologies, many said they had no access to the appropriate networks of mentors, investors, role models, and business partners necessary to begin the journey.

“We encourage you to become this network that has been missing,” Hickey told the awards event audience, which included an array of leaders in the biotech world. “Get to know our amazing faculty members and continue to support them. Become a part of this movement.”

How a quantum scientist, a nurse, and an economist are joining the fight against global poverty

A trip to Ghana changed Sofia Martinez Galvez’s life. In 2021, she volunteered at a nonprofit that provides technology and digital literacy training to people in the West African country. As she was setting up computers and connecting cables, Martinez SM ʼ23 witnessed extreme poverty. The experience was transformative. That same year, she left her job in quantum cryptography in Spain and enrolled in the MITx MicroMasters online program in Data, Economics, and Design of Policy (DEDP), which teaches learners how to use data-driven tools to help end global poverty.

By 2023, Martinez completed the MIT DEDP master’s program. Today, she is the co-founder of Learning Alliance, a new nonprofit that will counter sub-Saharan Africa’s learning crisis by introducing evidence-based teaching practices to teachers. She plans to move to Africa this summer.

“If someone told me a few years ago, when I was doing research in quantum physics, that I would be starting my own organization at the intersection of education and poverty, I would have said they were crazy,” Martinez says. “From my first MicroMasters course, I knew I made the right choice. The instructors used mathematics, models, and data to understand society.”

Since 2017, the MicroMasters in DEDP program — jointly led by the Abdul Latif Jameel Poverty Action Lab (J-PAL) and MIT Open Learning — has been bringing together former nurses, lawyers, software developers, and others who are ready to make a career change and an impact on the world.

A new way to combat poverty

The MicroMasters in DEDP curricula is based on the Nobel Prize-winning work of MIT faculty members Esther Duflo, the Abdul Latif Jameel Professor of Poverty Alleviation and Development Economics, and Abhijit Banerjee, the Ford Foundation International Professor of Economics.

The pair used a key feature of laboratory science — randomized control trials — and applied it to development economics. For example, to test the efficacy of a new education initiative, researchers could randomly assign individuals to either participate in the program, known as the treatment group, or not, known as the control group. The difference in outcomes can be attributed to the new program.

This approach has fundamentally changed how antipoverty programs are designed and evaluated around the world. It has already boosted immunization rates in India, reduced child marriages in Bangladesh, and increased school attendance in Kenya. 

Duflo and Banerjee’s research created a new way forward for poverty alleviation, but there are too few people skilled in evidence-based development economics to bring about meaningful change, says Sara Fisher Ellison, faculty director of the MicroMasters and master’s programs in DEDP and a senior lecturer in the MIT Department of Economics.

“It is vitally important that we have people all over the world who have the skills to run randomized control trials, to read the literature from these trials, and interpret the results to policymakers,” Ellison says.

Andrea Salem was an economics undergraduate student in Switzerland who was unsure about his career when Duflo and Banerjee received their Nobel Prize. Their recognition introduced Salem to a field he barely knew existed, and set him on a path toward using economics to make an impact in the world.

He completed the MicroMasters in DEDP credential and included it in his application for the Paris School of Economics (PSE). Currently taking a gap year from PSE, Salem has an internship with J-PAL’s Morocco Employment Lab. In this role, he works with government officials to evaluate education reforms.

“To get to know the world in all its diversity is a gift,” Salem says. “To live and do research in the same country is a reminder of the important work I’m doing and how much more needs to be done.”

How the DEDP program works

The MicroMasters in DEDP program is open to anyone with a reliable internet connection. Students choose either a track in public policy, which focuses on key issues in high-income countries, or international development, which examines problems prevalent in low- and middle-income countries. They take a rigorous course load in economics, probability and statistics, and data analysis. The program balances flexibility with structure. Students go at their preferred pace in earning the credential, but each course is instructor-led, providing participants with a community of global learners who can regularly participate in webinars and discussion forums.

Students who complete and pass proctored exams in five courses earn a credential. The MicroMasters in DEDP program has awarded more than 10,000 certificates for passed courses and 1,000 DEDP MicroMasters credentials. Credential holders may continue their education by applying to a master’s program at MIT or at one of 19 pathway universities worldwide that either recognize the MicroMasters in DEDP credential in admissions or offer academic credit for the credential as part of an accelerated graduate program. The credential itself is also valuable for professionals as they advance their careers.

The courses are free to audit; there is a fee for each proctored exam. Exam fees are on a sliding scale, ranging from $250 to $1,000, based on a learner’s income and location. DEDP also offers a lottery, available to people who earn less than $10,000 a year, that discounts the price of one course to $100. Martinez was a beneficiary of the lottery in 2021. Without it, she says it would have taken her longer to earn her credential and apply to the master’s program.

Choosing passion and pedigree

Yann Bourgeois SM ʼ22 had a rewarding nursing career working in operating rooms and intensive care units in Belgium. This job gave Bourgeois a firsthand understanding of what happens when human health and needs are neglected. Driven to make a global impact, Bourgeois discovered the master’s in DEDP program while studying public health.

Having overcome personal challenges and socioeconomic adversity, Bourgeois was not sure MIT would consider him for graduate school. When he learned that the MicroMasters credential played an important role in admissions, Bourgeois became hopeful. He enrolled in five MicroMasters in DEDP classes at the same time. It was a bold move for someone who had not taken a math class beyond statistics, but he was eager to submit his graduate school application. By 2022, Bourgeois was an MIT graduate.

“My background doesn’t matter,” Bourgeois says. “The fact that I didn’t know what I wanted to do with my life at 14 or 15 doesn’t matter. All that matters is the skills and passion.”

Bourgeois now works as a labor economist at the World Bank in Washington. His job focuses on improving labor conditions and promoting equitable economic opportunities. His MIT education equipped Bourgeois with rigorous analytical tools to address complex economic problems on an international scale.

Like Bourgeois, Martinez did not believe she had the qualifications to apply for the master’s in DEDP program. Then, she read students’ profiles online and learned about their wide-ranging experiences. After learning more about the program’s inverted admissions process, which prioritizes performance in relevant courses over traditional credentials, she realized that the opportunity might not be out of reach.

“Evidence-based development needs people from very diverse backgrounds,” Martinez says. “And I’m proof that you don’t need the ‘right’ background to work in development economics. The fight against global poverty needs everyone.”

Catalyst Symposium helps lower “activation barriers” for rising biology researchers

For science — and the scientists who practice it — to succeed, research must be shared. That’s why members of the MIT community recently gathered to learn about the research of eight postdocs from across the country for the second annual Catalyst Symposium, an event co-sponsored by the Department of Biology and The Picower Institute for Learning and Memory.

The eight Catalyst Fellows came to campus as part of an effort to increase engagement between MIT scholars and postdocs excelling in their respective fields from traditionally underrepresented backgrounds in science. The three-day symposium included panel discussions with faculty and postdocs, one-on-one meetings, social events, and research talks from the Catalyst Fellows.

“I love the name of this symposium because we’re all, of course, eager to catalyze advancements in our professional lives, in science, and to move forward faster by lowering activation barriers,” says MIT biology department head Amy Keating. “I feel we can’t afford to do science with only part of the talent pool, and I don’t think people can do their best work when they are worried about whether they belong.” 

The 2024 Catalyst Fellows include Chloé Baron from Boston Children’s Hospital; Maria Cecília Canesso from The Rockefeller University; Kiara Eldred from the University of Washington School of Medicine; Caitlin Kowalski from the University of Oregon; Fabián Morales-Polanco from Stanford University; Kali Pruss from the Washington University School of Medicine in St. Louis; Rodrigo Romero from Memorial Sloan Kettering Cancer Center; and Zuri Sullivan from Harvard University.

Romero, who received his PhD from MIT working in the Jacks Lab at the Koch Institute, said that it was “incredible to see so many familiar faces,” but he spent the symposium lunch chatting with new students in his old lab.

“Especially having been trained to think differently after MIT, I can now reach out to people that I didn’t as a graduate student, and make connections that I didn’t think about before,” Romero says.

He presented his work on lineage plasticity in the tumor microenvironment. Lineage plasticity is a hallmark of tumor progression but also occurs during normal development, such as wound healing.

As for the general mission of the symposium, Romero agrees with Keating.

“Trying to lower the boundary for other people to actually have a chance to do academic research in the future is important,” Romero says.

The Catalyst Symposium is aimed at early-career scientists who foresee a path in academia. Of the 2023 Catalyst Fellows, one has already secured a faculty position. Starting this September, Shan Maltzer will be an assistant professor at Vanderbilt University in the Department of Pharmacology and the Vanderbilt Brain Institute studying mechanisms of somatosensory circuit assembly, development, and function.

Another aim of the Catalyst Symposium is to facilitate collaborations and strengthen existing relationships. Sullivan, an immunologist and molecular neuroscientist who presented on the interactions between the immune system and the brain, is collaborating with Sebastian Lourido, an associate professor of biology and core member of the Whitehead Institute for Biomedical Research. Lourido’s studies include pathogens such as Toxoplasma gondii, which is known to alter the behavior of infected rodents. In the long term, Sullivan hopes to bridge research in immunology and neuroscience — for instance by investigating how infection affects behavior. She has observed that two rodents experiencing illness will huddle together in a cage, whereas an unafflicted rodent and an ill one will generally avoid each other when sharing the same space.

Pruss presented research on the interactions between the gut microbiome and the environment, and how they may affect physiology and fetal development. Kowalski discussed the relationship between fungi residing on our bodies and human health. Beyond the opportunity to deliver talks, both agreed that the small group settings of the three-day event were rewarding.

“The opportunity to meet with faculty throughout the symposium has been invaluable, both for finding familiar faces and for establishing friendly relationships,” Pruss says. “You don’t have to try to catch them when you’re running past them in the hallway.”

Eldred, who studies cell fate in the human retina, says she was excited about the faculty panels because they allowed her to ask faculty about fundamental aspects of recruiting for their labs, like bringing in graduate students.

Kowalski also says she enjoyed interfacing with so many new ideas — the spread of scientific topics from among the cohort of speakers extended beyond those she usually interacts with.

Mike Laub, professor of biology and Howard Hughes Medical Institute investigator, and Yadira Soto-Feliciano, assistant professor of biology and intramural faculty at the Koch Institute for Integrative Cancer Research, were on the symposium’s planning committee, along with Diversity, Equity, and Inclusion Officer Hallie Dowling-Huppert. Laub hopes the symposium will continue to be offered annually; next year’s Catalyst Symposium is already scheduled to take place in early May.

“I thought this year’s Catalyst Symposium was another great success. The talks from the visiting fellows featured some amazing science from a wide range of fields,” Laub says. “I also think it’s fair to say that their interactions with the faculty, postdocs, and students here generated a lot of excitement and energy in our community, which is exactly what we hoped to accomplish with this symposium.”

Metal Slug Tactics Preview – A Promising And Challenging Boot Camp – Game Informer

Metal Slug made its name as a fast-paced, run-and-gun explosive arcade shooter, making it all the more surprising how well it seemingly fits into a slower, turn-based strategy format. Since Metal Slug Tactics’ reveal at the final E3 in 2021, both series fans and tactics aficionados have been waiting with bated breath to get their hands on it. I count myself among them and was anxious to play a preview build to finally see how well this marriage of genres blends. 

The demo gives me command of three available characters: Marco, Eri, and Fio (with a fourth, Tarma, unlockable later). Each is armed with a primary weapon, a secondary special weapon, and can sport unique passive skills and active abilities called Special Actions. For example, Marco emphasizes relentless offense, and his Salvo special action grants himself or an ally an extra hit for a single attack. Eri, the explosive expert, has a special action that lets her lob two explosives instead of one. Fio favors long-range and can manipulate enemy compositions by sending a drone that can pluck units or allies and drop them to another nearby square. Special Actions are activated by spending Adrenaline, the game’s term for mana points. The mechanic Tarma boasts a knife for close-range offense, a shotgun, and can blow into foes with his motorcycle special action. 

The demo offers one region, Argun Palm Desert, but I spot three locked regions for a likely total of four in the game. The villainous Abul Abbas’ army has occupied this desert and its rural villages, putting civilians in harm’s way. It’s my job to pry the region from his clutches, which is presented as a world map with eight missions I can tackle in any order. However, you can only complete four before the boss arrives, indicated by a countdown at the top of the screen. Each mission features a primary objective and a secondary, optional task (such as winning without losing a unit or finishing without taking damage). Both offer unique rewards such as XP gain, coins (which can be turned in for cash), weapon mods, or additional reinforcements. Since you can only tackle a mission connected to an adjacent, completed mission, it’s important to plot the ideal route to collect the resources you want/need. 

[embedded content]

Primary mission objectives include wiping out select targets, escaping to an exit, surviving a number of rounds, safely escorting an ally, and destroying a convoy before it leaves the map. Rounds begin by placing units in designated starting zones. Metal Slug Tactics features standard grid-based movement, and maps often include numerous destructible cover points. Placing units in these blue-coded protective spots reduces incoming damage, even when hit from the exposed side of the cover. My favorite element of stages is interactable hazards that can help eliminate foes without spending precious movement/attack points. This includes activating a crane to drop a suspended crate that crushes anyone underneath it. My favorite is shooting a pot to awaken a sleeping cobra that strikes anyone within its range, maiming multiple foes single-handedly (or technically zero-handedly) while also forcing them to navigate around it until it falls asleep again. 

Primary weapons, such as a handgun or, in Eri’s case, a grenade, have unlimited ammo. Conversely, the more powerful special weapons, like a machine gun or grenade launcher, have limited ammo. Managing the use of your second weapon is critical, as you’re only allotted that ammo throughout your entire campaign, though replenishing ammo is a reward for certain objectives. The basic flow of positioning units in line with enemies to riddle them with bullets gets more interesting by lining up sync attacks. By targeting a foe within the same firing range as an ally, that character will automatically attack the target with their primary weapon right after you do. This allows you to unleash a tag-team or even triple-team assault if you play your cards right. However, an enemy can only suffer one sync attack per turn. It’s a fun system that has me thoughtfully considering the placement of each character and feels puzzle-like in discovering ways to maximize each attack. 

In true Metal Slug fashion, some stages include tanks you can hop into, and they’re great for quickly traversing the stage. Most importantly, tanks unleash a limited number of wide-reaching cannon fire dictated by their fuel count. In addition to dealing tons of damage, tanks serve as useful protective shells for characters on the brink of death. You can also earn Assets, special consumable items used in battle, such as airdropping the titular Metal Slug to wreak havoc. If a unit falls, you can revive them by calling reinforcements. However, this consumes a reinforcement point. You only have six of these for the entire campaign and can only replenish them by completing missions that reward an additional point. 

Completing missions earns medals used to upgrade a character’s special action, improving its effectiveness and sometimes lowering its Adrenaline cost. Leveling up a character unlocks an additional special action from a randomized pool of three. Arsenal rewards offer a choice of three weapon mods. Primary weapons can equip two mods, while special weapons hold up to three. Stacking weapons with mods is crucial as it makes them more well-rounded and can be equipped to suit your playstyle. For example, a mod can increase the magazine size of the special weapon or make sync attacks more powerful for participating allies.

After I finish four missions, the boss arrives in the form of Bige Shiee, an overly armed gunship fans may remember from Metal Slug 2. In addition to chipping away at this sturdy foe, which launches wide-reaching missile blasts with a one-turn warning, I have to face a plethora of grunts. Additionally, the floating docks serving as our battlefield gradually crumbled and sank into the ocean, forcing you to keep moving and not camp in an advantageous position for too long. 

Failing a mission sends you back to the outpost, where you’re greeted with new cutscenes, usually introducing a new character, such as Margaret, your commander, or the backpack lugging Rumi, who hangs out at the outpost to offer some kind of service. Rumi sells new weapons and mods, and you unlock new character abilities with Margaret. You can also purchase entire load-outs, presenting a full set of weapons and abilities favoring, for example, close-quarter play or one loadout that favors creating sync attacks. Your cumulative performance throughout all completed missions determines your payout, such as the number of missions you completed and the number of sync attacks executed by each character.

Once you’ve kitted yourself out, its off to start the campaign anew. That’s right; Metal Slug Tactics is a roguelite at its core. Starting a new campaign means completing missions all over again, though the selection and rewards are remixed each time. The introductory mission briefing features dialogue exchanges. All of your unlocked special actions and passives reset, too, leaving you with your permanent starting skill for each. 

Because of this structure, the early runs of Metal Slug Tactics are quite difficult. I consider myself an experienced tactics player, but even on the lowest available difficulty, many early battles feel like a war of attrition, as conflicts often throw upwards of 15 enemy units against my mere trio. It also doesn’t help that most mission types continually introduce baddie reinforcements. At the start, your units don’t have much health and can be taken out quickly by two or three attacks. With limited revives and no way to heal units (initially, at least), I felt like I was fighting from underneath most of the time.

The “escape to the exit” objectives are the most maddening due to the absurd amount of bad guys thrown at you versus your low HP count. Beelining for the exit often meant I was torn to pieces, but gradually picking off threats and inching toward the goal took ages, only for new enemies to arrive and replace downed ones. I finished most missions with only one living squad member clinging to life. 

Strict resource management contributes to this challenge. Since your special weapon has limited ammo throughout the entire campaign, careless usage means you could enter a boss fight with only your basic pistol. At the same time, special weapons wipe out units much faster than your primary one, and the longer a mission lasts, the more the advantage often tilts toward your opposition. This is especially true if you want to fulfill the secondary goals, such as completing missions within two to three turns. 

Because of the game’s run-based nature, you’ll likely struggle to get through missions for a while until you get some new abilities or gear under your belt. I performed noticeably better in my subsequent runs, but it took several repeated campaign runs before I felt like I could somewhat hold my own. That said, once I lasted long enough to accrue a solid stable of abilities to play with, building loadouts that complimented an individual’s specialty as well as the team’s dynamic became an enjoyable, strategically stimulating process. Still, climbing that initially steep difficulty wall may be an early turn-off for players expecting a more balanced experience from the outset. 

Metal Slug Tactics’ presentation looks great, thanks to the series’ charming sprites and animations. A catchy soundtrack courtesy of Tee Lopes is the melodic cherry on top. Despite the early roadblocks, I gradually developed a callus to Metal Slug Tactics’ hardships and saw more consistent victories. Once I hit a groove, it became an enjoyable and strategically satisfying romp. I’m still worried about its overall balancing, but there’s definitely promise for Metal Slug Tactics to be a mission: success.

AI Set To Take Center Stage at Today’s Apple WWDC Conference

Apple’s annual Worldwide Developers Conference (WWDC) is set to take center stage today with AI expected to be the main focus. The WWDC event serves as a platform for Apple to showcase its latest software innovations and features, making it a highly anticipated gathering for developers…

Protein study could help researchers develop new antibiotics

A bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a “hydrophobic” protein that loses its structure once removed from its normal location in the cell membrane.

Now, an MIT-led team has found a way to make the enzyme water-soluble, which could make it possible to rapidly screen potential drugs that might interfere with its functions.

The researchers created their new version of histidine kinase by replacing four specific hydrophobic amino acids with three hydrophilic ones. Even after this significant shift, they found that the water-soluble version of the enzyme retained its natural functions.

No existing antibiotics target histidine kinase, so drugs that disrupt these functions could represent a new class of antibiotics. Such drug candidates are badly needed to combat the growing problem of antibiotic resistance.

“Each year, more than 1 million people die from antibiotic-resistant infections,” says Shuguang Zhang, a principal research scientist in the MIT Media Lab and one of the senior authors of the new study. “This protein is a good target because it’s unique to bacteria and humans don’t have it.”

Ping Xu and Fei Tao, both professors at Shanghai Jiao Tong University, are also senior authors of the paper, which appears today in Nature Communications. Mengke Li, a graduate student at Shanghai Jiao Tong University and a former visiting student at MIT, is the lead author of the paper.

A new drug target

Many of the proteins that perform critical cell functions are embedded in the cell membrane. The segments of these proteins that span the membrane are hydrophobic, which allows them to associate with the lipids that make up the membrane. However, once removed from the membrane, these proteins tend to lose their structure, which makes it difficult to study them or to screen for drugs that might interfere with them.

In 2018, Zhang and his colleagues devised a simple way to convert these proteins into water-soluble versions, which maintain their structure in water. Their technique is known as the QTY code, for the letters that represent the hydrophilic amino acids that become incorporated into the proteins. Leucine (L) becomes glutamine (Q), isoleucine (I) and valine (V) become threonine (T), and phenylalanine (F) becomes tyrosine (Y).

Since then, the researchers have demonstrated this technique on a variety of hydrophobic proteins, including antibodies, cytokine receptors, and transporters. Those transporters include a protein that cancer cells use to pump chemotherapy drugs out of the cells, as well as transporters that brain cells use to move dopamine and serotonin into or out of cells.

In the new study, the team set out to demonstrate, for the first time, that the QTY code could be used to create water-soluble enzymes that retain their enzymatic function.

The research team chose to focus on histidine kinase in part because of its potential as an antibiotic target. Currently most antibiotics work by damaging bacterial cell walls or interfering with the synthesis of ribosomes, the cell organelles that manufacture proteins. None of them target histidine kinase, an important bacterial protein that regulates processes such as antibiotic resistance and cell-to-cell communication.

Histidine kinase can perform four different functions, including phosphorylation (activating other proteins by adding a phosphate group to them) and dephosphorylation (removing phosphates). Human cells also have kinases, but they act on amino acids other than histidine, so drugs that block histidine kinase would likely not have any effect on human cells.

After using the QTY code to convert histidine kinase to a water-soluble form, the researchers tested all four of its functions and found that the protein was still able to perform them. This means that this protein could be used in high-throughput screens to rapidly test whether potential drug compounds interfere with any of those functions.

A stable structure

Using AlphaFold, an artificial intelligence program that can predict protein structures, the researchers generated a structure for their new protein and used molecular dynamics simulations to investigate how it interacts with water. They found that the protein forms stabilizing hydrogen bonds with water, which help it keep its structure.

They also found that if they only replaced the buried hydrophobic amino acids in the transmembrane segment, the protein would not retain its function. The hydrophobic amino acids have to be replaced throughout the transmembrane segment, which helps the molecule maintain the structural relationships it needs to function normally.

Zhang now plans to try this approach on methane monooxygenase, an enzyme found in bacteria that can convert methane into methanol. A water-soluble version of this enzyme could be sprayed at sites of methane release, such as barns where cows live, or thawing permafrost, helping to remove a large chunk of methane, a greenhouse gas, from the atmosphere.

“If we can use the same tool, the QTY code, on methane monooxygenase, and use that enzyme to convert methane into methanol, that could deaccelerate climate change,” Zhang says.

The QTY technique could also help scientists learn more about how signals are carried by transmembrane proteins, says William DeGrado, a professor of pharmaceutical chemistry at the University of California at San Francisco, who was not involved in the study.

“It is a great advance to be able to make functionally relevant, water-solubilized proteins,” DeGrado says. “An important question is how signals are transmitted across membranes, and this work provides a new way to approach that question.”  

The research was funded, in part, by the National Natural Science Foundation of China. 

Profile Bakery Review: AI Headshots for Job Seekers & More

Now more than ever, having a high-quality profile picture is essential, whether for social media, professional websites, or job applications. However, not everyone has the time or budget to hire a professional photographer. I recently came across Profile Bakery, an AI headshot generator that turns your…

Polaris Is A Co-Op PvE Shooter Coming To PC This Year With Fully Destructible Environments

Polaris is a four-player co-op PvE shooter set in an original sci-fi universe coming to PC via Steam this year. Developed by Polaris Team, an offshoot of Variable State, which is the studio behind 2021’s Last Stop and 2016’s Virginia, the developer formally unveiled Polaris during today’s IGN Live showcase with a cinematic trailer. 

In the trailer, we get a glimpse of this sci-fi world, which takes place in a region of space overtaken by a ruthless force known simply as the Regime. In the game, players must reclaim their homeworlds and bring every enemy stronghold down. 

Check out the game’s first look in the Polaris reveal trailer below

[embedded content]

Polaris Team says, “All in-game structures – installed by the Regime, but not yet inhabited by their indoctrinated citizens – can be crushed, blown apart, and otherwise annihilated over the course of every match, and the same is true of the natural environments and terrain upon which they’ve been constructed.” 

Players control superpowered freedom fighters who utilize guerrilla tactics to take back their territory while flying through dynamic open levels, destroying enemy infrastructure, and unearthing coveted mysteries that drive the Regime’s war of conquest. 

“Since I first played Bullfrog’s Syndicate Wars, I’ve always dreamed of working on a game that featured hi-tech squads of futuristic soldiers, causing mayhem and destruction in an original sci-fi setting,” Polaris Team creative director Jonathan Burroughs writes in a press release. “Sprinkle in a deep appreciation for the Halo series – particularly its blend of on-foot and in-vehicle co-op action – and you can begin to get a sense of what we hope to achieve with Polaris. 

“We’re only a small and scrappy team of 11 people, but have been plugging away at this project since early 2023. Aided by the tools and technologies of Unreal Engine 5, Polaris Team has built a tight 4-player PvE combat game with a dynamic, destructible environment set in our own unique sci-fi universe. With the release date arriving later this year, the team and I couldn’t be more excited to share Polaris with players worldwide!”

Here are some Polaris screenshots to check out

Polaris is due out on PC via Steam sometime this year. You can sign up for a beta playtest starting today. 


What do you think of Polaris’ reveal? Let us know in the comments below!